EUVIMEDEUVIMED entdecken
Crossref

Radiomic signatures of meningiomas using the Ki-67 proliferation index as a prognostic marker of clinical outcomes

Omaditya Khanna, Anahita Fathi Kazerooni, Sherjeel Arif, Aria Mahtabfar, Arbaz A Momin, Carrie E Andrews, Karim Hafazalla, Michael P Baldassari, Lohit Velagapudi, Jose A Garcia, Chiharu Sako, Christopher J Farrell und 6 weitere

Neurosurgical Focus · 2023-06 · 54 (6) · E17

DOI: 10.3171/2023.3.focus2337 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurosurgical Focus, 2023-06. Verfasst von Omaditya Khanna und 17 weiteren Autor:innen. Beteiligte Einrichtung: Departments of1Neurological Surgery and. Hauptthemen laut MEDLINE: Meningioma, Meningeal Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 90 Literaturangaben. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE The clinical behavior of meningiomas is not entirely captured by its designated WHO grade, therefore other factors must be elucidated that portend increased tumor aggressiveness and associated risk of recurrence. In this study, the authors identify multiparametric MRI radiomic signatures of meningiomas using Ki-67 as a prognostic marker of clinical outcomes independent of WHO grade. METHODS A retrospective analysis was conducted of all resected meningiomas between 2012 and 2018. Preoperative MR images were used for high-throughput radiomic feature extraction and subsequently used to develop a machine learning algorithm to stratify meningiomas based on Ki-67 indices < 5% and ≥ 5%, independent of WHO grade. Progression-free survival (PFS) was assessed based on machine learning prediction of Ki-67 strata and compared with outcomes based on histopathological Ki-67. RESULTS Three hundred forty-three meningiomas were included: 291 with WHO grade I, 43 with grade II, and 9 with grade III. The overall rate of recurrence was 19.8% (15.1% in grade I, 44.2% in grade II, and 77.8% in grade III) over a median follow-up of 28.5 months. Grade II and III tumors had higher Ki-67 indices than grade I tumors, albeit tumor and peritumoral edema volumes had considerable variation independent of meningioma WHO grade. Forty-six high-performing radiomic features (1 morphological, 7 intensity-based, and 38 textural) were identified and used to build a support vector machine model to stratify tumors based on a Ki-67 cutoff of 5%, with resultant areas under the curve of 0.83 (95% CI 0.78–0.89) and 0.84 (95% CI 0.75–0.94) achieved for the discovery (n = 257) and validation (n = 86) data sets, respectively. Comparison of histopathological Ki-67 versus machine learning–predicted Ki-67 showed excellent performance (overall accuracy > 80%), with classification of grade I meningiomas exhibiting the greatest accuracy. Prediction of Ki-67 by machine learning classifier revealed shorter PFS for meningiomas with Ki-67 indices ≥ 5% compared with tumors with Ki-67 < 5% (p < 0.0001, log-rank test), which corroborates divergent patient outcomes observed using histopathological Ki-67. CONCLUSIONS The Ki-67 proliferation index may serve as a surrogate marker of increased meningioma aggressiveness independent of WHO grade. Machine learning using radiomic feature analysis may be used for the preoperative prediction of meningioma Ki-67, which provides enhanced analytical insights to help improve diagnostic classification and guide patient-specific treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeningiomaMeningeal NeoplasmsHumansKi-67 AntigenRetrospective StudiesPrognosisCell Proliferation

Stichwörter der Autor:innen

Ki-67 proliferation indexmachine learningmeningiomaradiomics

Substanzen

Ki-67 Antigen

Autor:innen und Institutionen

  • Departments of1Neurological Surgery and.
  • 2Center for Biomedical Image Computing and Analytics and.
  • 3Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; and.
  • 4Radiology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.
  • 5Department of Radiation Oncology, Sidney Kimmel Medical College & Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.

Förderung

  • NCI NIH HHS

Zitieren

APA

Khanna, O., Fathi Kazerooni, A., Arif, S., Mahtabfar, A., Momin, A. A., Andrews, C. E., Hafazalla, K., Baldassari, M. P., Velagapudi, L., Garcia, J. A., Sako, C., Farrell, C. J., Evans, J. J., Judy, K. D., Andrews, D. W., Flanders, A. E., Shi, W., & Davatzikos, C. (2023). Radiomic signatures of meningiomas using the Ki-67 proliferation index as a prognostic marker of clinical outcomes. Neurosurgical Focus, 54(6), E17. https://doi.org/10.3171/2023.3.focus2337

Vancouver

Khanna O, Fathi Kazerooni A, Arif S, Mahtabfar A, Momin AA, Andrews CE, et al. Radiomic signatures of meningiomas using the Ki-67 proliferation index as a prognostic marker of clinical outcomes. Neurosurgical Focus. 2023;54(6):E17. doi:10.3171/2023.3.focus2337

BibTeX
@article{Khanna2023,
  author = {Khanna, Omaditya and Fathi Kazerooni, Anahita and Arif, Sherjeel and Mahtabfar, Aria and Momin, Arbaz A and Andrews, Carrie E and Hafazalla, Karim and Baldassari, Michael P and Velagapudi, Lohit and Garcia, Jose A and Sako, Chiharu and Farrell, Christopher J and Evans, James J and Judy, Kevin D and Andrews, David W and Flanders, Adam E and Shi, Wenyin and Davatzikos, Christos},
  title = {Radiomic signatures of meningiomas using the Ki-67 proliferation index as a prognostic marker of clinical outcomes},
  journal = {Neurosurgical Focus},
  year = {2023},
  volume = {54},
  number = {6},
  pages = {E17},
  doi = {10.3171/2023.3.focus2337}
}
Kostenlos starten →